Physician profile
Stacey L Epps
NPI 1154391571
$108,864.74
in general payments reported to CMS, 2019-2025
70 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $6,852 · 2021: $15K · 2022: $9,144 · 2023: $3,924 · 2024: $13K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Food and Beverage: $8,994 · Consulting Fee: $7,585 · Travel and Lodging: $1,562 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,800.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,232.50 |
| Food and Beverage | $8,994.06 |
| Consulting Fee | $7,585.00 |
| Travel and Lodging | $1,562.41 |
| Education | $230.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27,798.96 | 2019-2023 | Austedo Xr, Austedo, Ajovy |
| Eisai INC. | $22,660.35 | 2019-2025 | |
| Lilly USA, LLC | $20,929.46 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Genzyme Corporation | $15,418.29 | 2019-2023 | |
| Ucb, INC. | $2,953.74 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Livanova USA, INC. | $2,299.41 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic USA, INC. | $1,385.26 | 2020 | |
| Biogen, INC. | $1,359.08 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Novartis Pharmaceuticals Corporation | $1,310.90 | 2019-2023 | |
| Sk Life Science, INC. | $1,109.92 | 2020-2025 | Xcopri |
| Abbvie INC. | $981.92 | 2020-2024 | |
| Alexion Pharmaceuticals, INC. | $759.62 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $701.13 | 2019-2025 | Uplizna |
| Emd Serono, INC. | $660.92 | 2019-2023 | Mavenclad |
| Lundbeck LLC | $587.63 | 2019-2025 | Vyepti, Rexulti |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Epps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.